콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

C0246

Sigma-Aldrich

Cabergoline

≥98% (HPLC)

동의어(들):

1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea, 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea, Cabaser, Dostinex, FCE-21336

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C26H37N5O2
CAS Number:
81409-90-7
Molecular Weight:
451.60
MDL number:
MFCD00867887
UNSPSC 코드:
12352200
PubChem Substance ID:
329774771
NACRES:
NA.77

분석

≥98% (HPLC)

형태

powder

광학 활성

[α]/D −63 to −74°, c = 0.5 in dichloromethane

solubility

DMSO: ≥10 mg/mL

주관자

Johnson & Johnson

저장 온도

2-8°C

SMILES string

CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1

InChI

1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

InChI key

KORNTPPJEAJQIU-KJXAQDMKSA-N

유전자 정보

human ... DRD2(1813)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

생화학적/생리학적 작용

Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).

특징 및 장점

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

픽토그램

Exclamation mark
GHS07

신호어

Warning

유해 및 위험 성명서

H302,H362

Hazard Classifications

Acute Tox. 4 Oral - Lact.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Samuel Santos-Ribeiro et al.
Journal of assisted reproduction and genetics, 32(7), 1063-1068 (2015-05-20)
We report on the results of the whole-genome analysis performed in a patient who developed severe ovarian hyperstimulation syndrome (OHSS) following gonadotropin-releasing hormone (GnRH) agonist triggering in a "freeze-all" protocol. A 30-year-old patient with polycystic ovary syndrome who developed severe
Rivka Inzelberg et al.
Drugs & aging, 20(11), 847-855 (2003-09-11)
Dopamine agonists have been widely used as add-on to levodopa in the treatment of Parkinson's disease with motor fluctuations. However, the use of dopamine agonists in early Parkinson's disease and levodopa-naive patients is controversial. Although dopamine agonists have been compared
Paolo Del Dotto et al.
Clinical pharmacokinetics, 42(7), 633-645 (2003-07-08)
Cabergoline is a synthetic ergoline dopamine agonist with a high affinity for D(2) receptors indicated for use in both early and advanced Parkinson's disease and in hyperprolactinaemic disorders. Following oral administration, peak plasma concentrations of cabergoline are reached within 2-3
Vania dos Santos Nunes et al.
Pituitary, 14(3), 259-265 (2011-01-12)
Cabergoline and bromocriptine are the most used drugs in the treatment of hyperprolactinemia, they are able to normalize the prolactin levels, restore gonadal function and promote tumor reduction in the majority of patients. We undertake a systematic review and meta-analysis
Monique P Curran et al.
Drugs, 64(18), 2125-2141 (2004-09-03)
Cabergoline is a synthetic ergoline dopamine agonist with a high affinity for dopamine D2 receptors and a long elimination half-life. This agent provides continuous dopaminergic stimulation with once-daily administration. Adjuvant oral cabergoline is usually well tolerated and effective in controlling
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.